Dimerix, Takeda in GPCR Screening Pact

The Australian company will use its GPCR-HIT platform to help Takeda Cambridge study potential drug candidate compounds.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.